|
 Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity
|
|
|
|
PUBLIKATION
(26.01.2009)
: Mendoza-Ferri MG, Hartinger CG, Mendoza MA, Groessl M, Egger AE, Eichinger RE, Mangrum JB, Farrell NP, Maruszak M, Bednarski PJ, Klein F, Jakupec MA, Nazarov AA, Severin K, Keppler BK.
J Med Chem. 2009 Jan 26. [Epub ahead of print]
|
|
Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established anticancer compounds. Transferring this concept to ruthenium complexes led to the synthesis of dinuclear Ru(II)-arene compounds containing a bis(pyridinone)alkane ligand linker. A pronounced influence of the spacer length on the in vitro anticancer activity was found, which is correlated to the lipophilicity of the complexes. IC(50) values in the same dimension as for established platinum drugs were found in human tumor cell lines. No cross-resistance to oxoplatin, a cisplatin prodrug, was observed for the most active complex in three resistant cell lines; in fact, a 10-fold reversal of sensitivity in two of the oxoplatin-resistant lines was found. (Bio)analytical characterization of the representative examples showed that the ruthenium complexes hydrolyze rapidly, forming predominantly diaqua species that exhibit affinity toward transferrin and DNA, indicating that both proteins and nucleobases are potential targets.
PMID: 19170599 [PubMed - as supplied by publisher]
|
|
|
|
Informations- und Kommunikati...
für Projekte
pharmazie.uni-greifswald.de
